Biohaven Pharmaceutical Holding Company Ltd. – NYSE:BHVN

Add to watchlist

$15.49

-21.16

-57.75%

Market closed

Open in about 6 hours

-3.75%

month

-3.75%

quarter

-16.23%

year

Market Cap	3.61B
Enterprise value	613.08M

P/E	-1.1
EV/Sales	2.85
EV/EBITDA	-0.84
Price/Sales	3.66
Price/Book	1.46
PEG ratio	N/A
EPS	-6.83

Revenue	N/A
EBITDA	-537.78M
Income	-517.18M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-356.25%
Oper. margin	-291.12%
Gross margin	83.38%
EBIT margin	-291.12%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Biohaven Pharmaceutical Holding Company Ltd. Stock Forecast

M Q Y

Last Year

$60.6

Potential upside: 291.22%

Analysts Price target
Financials & Ratios estimates

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Profit margin
Jun 2023	0	-90.34M
Sep 2023	0	-102.57M
Dec 2023	0	-144.75M
Mar 2024	0	-179.50M

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Earnings per share (EPS)
2022-11-09	-1.30883	-1.75
2022-12-31	-7.11094	-3.78153
2023-03-23	-9.04966	-3.32

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Debt to assets
Jun 2023	506736000	119.48M	23.58%
Sep 2023	382736000	92.73M	24.23%
Dec 2023	513212000	85.23M	16.61%
Mar 2024	418532000	117.08M	27.98%

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Cash Flow
Jun 2023	-44.39M	76.25M	-20.33M
Sep 2023	-94.81M	58.54M	-39.65M
Dec 2023	-114.88M	-3.91M	210.05M
Mar 2024	-102.63M	34.03M	3.42M

Biohaven Pharmaceutical Holding Company Ltd. alternative data

Biohaven Pharmaceutical Holding Company Ltd.
Employees

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Employee count
Aug 2023	928
Sep 2023	928
Oct 2023	928
Nov 2023	928
Dec 2023	928
Jan 2024	202
Feb 2024	202
Mar 2024	239
Apr 2024	239
May 2024	239
Jun 2024	239
Jul 2024	239

Biohaven Pharmaceutical Holding Company Ltd.
Hedge Funds Holdings Q1 2022

98.17% +3.32%

of BHVN is owned by hedge funds

296 +21

hedge funds hold BHVN stock

63.49M +1.47M

shares is hold by hedge funds

BHVN hedge funds holdings changes

Biohaven Pharmaceutical Holding Company Ltd.
Insider Trading

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	150000	0
Oct 2023	949634	0
Dec 2023	0	11000
Apr 2024	391355	0
May 2024	71500	0
Jun 2024	30000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	17 Jun 2024	CAR BRUCE officer: Chief Sc..	Common Shares	30,000	$33.58	$1,007,490
Purchase	30 May 2024	CHILDS JOHN W director director	Common Shares	28,000	$35.58	$996,240
Purchase	13 May 2024	CHILDS JOHN W director director	Common Shares	28,500	$35.17	$1,002,459
Purchase	13 May 2024	BAILEY GREGORY director director	Common Shares	15,000	$34.19	$512,880
Purchase	24 Apr 2024	BAILEY GREGORY director director	Common Shares	25,503	$39.18	$999,182
Purchase	22 Apr 2024	BAILEY GREGORY director director	Common Shares	48,780	$41	$1,999,980
Purchase	22 Apr 2024	CHILDS JOHN W director director	Common Shares	97,560	$41	$3,999,960
Purchase	22 Apr 2024	CHILDS JOHN W director director	Common Shares	73,170	$41	$2,999,970
Purchase	22 Apr 2024	CHILDS JOHN W director director	Common Shares	24,391	$41	$1,000,031
Purchase	22 Apr 2024	CORIC VLAD director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Shares	121,951	$41	$4,999,991

BHVN insider trading transactions

Biohaven Pharmaceutical Holding Company Ltd.
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Prodrugs of riluzole and their method of use Filling date: 23 Nov 2020 Issue date: 13 Sep 2022	23 Nov 2020	13 Sep 2022
Application	Application FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY Filling date: 10 Apr 2020 Issue date: 11 Aug 2022	10 Apr 2020	11 Aug 2022
Grant	Grant Utility: Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers Filling date: 19 May 2017 Issue date: 2 Aug 2022	19 May 2017	2 Aug 2022
Application	Application USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES Filling date: 26 May 2019 Issue date: 14 Jul 2022	26 May 2019	14 Jul 2022
Grant	Grant Utility: Prodrugs of lanicemine and their method of use Filling date: 22 Nov 2017 Issue date: 14 Jun 2022	22 Nov 2017	14 Jun 2022
Application	Application PRODRUGS OF CGRP ANTAGONISTS Filling date: 10 Oct 2019 Issue date: 23 Dec 2021	10 Oct 2019	23 Dec 2021
Application	Application CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH Filling date: 19 Jan 2020 Issue date: 4 Nov 2021	19 Jan 2020	4 Nov 2021
Grant	Grant Utility: Rimegepant for CGRP related disorders Filling date: 27 May 2020 Issue date: 10 Aug 2021	27 May 2020	10 Aug 2021
Application	Application CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH Filling date: 17 Feb 2021 Issue date: 1 Jul 2021	17 Feb 2021	1 Jul 2021
Application	Application PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE Filling date: 23 Nov 2020 Issue date: 18 Mar 2021	23 Nov 2020	18 Mar 2021

BHVN patents

Biohaven Pharmaceutical Holding Company Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q4 2021 25 Feb 2022	Q4 2021 Earnings Call Transcript
Q3 2021 9 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 9 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 10 May 2021	Q1 2021 Earnings Call Transcript

BHVN earnings call transcripts

Biohaven Pharmaceutical Holding Company Ltd.
Executives

Insider	Age	Compensation
Dr. Vladimir Coric M.D. (1971) Chairman, Chief Executive Officer & Pres	54	$1,260,000
Mr. William Jones M.B.A. (1964) Chief Commercial Officer of Migraine & Common Diseases	61	$931,820
Dr. Elyse Stock M.D. (1958) Chief Medical Officer	67	$726,790
Ms. Kimberly Gentile (1966) Senior Vice President of Clinical Operations	59	$654,990

Biohaven Pharmaceutical Holding Company Ltd.
Latest News

Tuesday, 17 December 2024
14:23	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval	benzinga.com
Monday, 16 December 2024
07:30	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates	prnewswire.com
Friday, 6 December 2024
07:30	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting	prnewswire.com
Friday, 29 November 2024
05:30	Biohaven's Revenue Path: SCA And Obesity Therapies	seekingalpha.com
Monday, 25 November 2024
11:51	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study	benzinga.com
08:32	Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session	benzinga.com
07:45	Biohaven's spinal muscular atrophy drug fails to meet main goal in study	reuters.com
07:30	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity	prnewswire.com
Tuesday, 12 November 2024
16:05	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments	prnewswire.com
Wednesday, 2 October 2024
16:05	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	prnewswire.com
Tuesday, 1 October 2024
06:00	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares	prnewswire.com
Monday, 30 September 2024
16:05	Biohaven Announces Proposed Public Offering of Common Shares	prnewswire.com
07:30	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine	prnewswire.com
Tuesday, 24 September 2024
11:56	BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal	zacks.com
10:42	Biohaven Stock Soars on Drug Trial Results: Time to Jump In?	marketbeat.com
Monday, 23 September 2024
17:02	Overlooked Stock: BHVN	youtube.com
14:55	Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst	seekingalpha.com
14:40	Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug	investopedia.com
11:22	Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise	benzinga.com
09:18	Biohaven's stock surges as treatment slows progress of neurological disorder	marketwatch.com
09:11	Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease	investors.com
08:03	Biohaven's genetic disease drug meets main trial goal	reuters.com
07:30	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)	prnewswire.com
Friday, 20 September 2024
19:09	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia	prnewswire.com
Thursday, 8 August 2024
16:05	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments	prnewswire.com
Friday, 26 July 2024
11:48	Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment	seekingalpha.com
Friday, 28 June 2024
10:00	The 3 Smartest Healthcare Stocks to Buy With $1K Right Now	investorplace.com
Wednesday, 29 May 2024
09:12	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump	investors.com
07:30	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day	prnewswire.com
07:15	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	prnewswire.com

Ideas & Opinions

Seeking Alpha 5 May 2025

Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict
Seeking Alpha 18 Apr 2025

Xenon- A Later Stage Story
Seeking Alpha 20 Jan 2025

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Seeking Alpha 18 May 2024

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
Seeking Alpha 4 Apr 2024

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Seeking Alpha 1 Feb 2024

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Seeking Alpha 27 Mar 2023

Week In Review: Highlightll Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
Seeking Alpha 9 Mar 2023

Biohaven: Spun And Done - Time To Exit
Seeking Alpha 9 Jan 2023

Best Macro Pairs Trade Of 2023: Short ARKK And Long Healthcare
Seeking Alpha 7 Oct 2022

Biohaven Stub May Provide An Interesting Setup For Investors

Frequently Asked Questions (FAQ)

What's the price of Biohaven Pharmaceutical Holding Company Ltd. stock today?

One share of Biohaven Pharmaceutical Holding Company Ltd. stock can currently be purchased for approximately $15.49.
When is Biohaven Pharmaceutical Holding Company Ltd.'s next earnings date?

Unfortunately, Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) next earnings date is currently unknown.
Does Biohaven Pharmaceutical Holding Company Ltd. pay dividends?

No, Biohaven Pharmaceutical Holding Company Ltd. does not pay dividends.
How much money does Biohaven Pharmaceutical Holding Company Ltd. make?

Biohaven Pharmaceutical Holding Company Ltd. has a market capitalization of 3.61B. Biohaven Pharmaceutical Holding Company Ltd. made a loss 408.17M US dollars in net income (profit) last year or -$3.32 on an earnings per share basis.
What is Biohaven Pharmaceutical Holding Company Ltd.'s stock symbol?

Biohaven Pharmaceutical Holding Company Ltd. is traded on the NYSE under the ticker symbol "BHVN".
What is Biohaven Pharmaceutical Holding Company Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Biohaven Pharmaceutical Holding Company Ltd.?

Shares of Biohaven Pharmaceutical Holding Company Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Biohaven Pharmaceutical Holding Company Ltd.'s key executives?
Biohaven Pharmaceutical Holding Company Ltd.'s management team includes the following people:
- Dr. Vladimir Coric M.D. Chairman, Chief Executive Officer & Pres(age: 54, pay: $1,260,000)
- Mr. William Jones M.B.A. Chief Commercial Officer of Migraine & Common Diseases(age: 61, pay: $931,820)
- Dr. Elyse Stock M.D. Chief Medical Officer(age: 67, pay: $726,790)
- Ms. Kimberly Gentile Senior Vice President of Clinical Operations(age: 59, pay: $654,990)
How many employees does Biohaven Pharmaceutical Holding Company Ltd. have?

As Jul 2024, Biohaven Pharmaceutical Holding Company Ltd. employs 239 workers.
When Biohaven Pharmaceutical Holding Company Ltd. went public?

Biohaven Pharmaceutical Holding Company Ltd. is publicly traded company for more then 3 years since IPO on 23 Sep 2022.
What is Biohaven Pharmaceutical Holding Company Ltd.'s official website?

The official website for Biohaven Pharmaceutical Holding Company Ltd. is biohavenpharma.com.
Where are Biohaven Pharmaceutical Holding Company Ltd.'s headquarters?

Biohaven Pharmaceutical Holding Company Ltd. is headquartered at 215 Church Street, New Haven, CT.
How can i contact Biohaven Pharmaceutical Holding Company Ltd.?

Biohaven Pharmaceutical Holding Company Ltd.'s mailing address is 215 Church Street, New Haven, CT and company can be reached via phone at +20 3 4040410.
What is Biohaven Pharmaceutical Holding Company Ltd. stock forecast & price target?

Based on 8 Wall Street analysts` predicted price targets for Biohaven Pharmaceutical Holding Company Ltd. in the last 12 months, the avarage price target is $60.6. The average price target represents a 291.22% change from the last price of $15.49.

Biohaven Pharmaceutical Holding Company Ltd.

biohavenpharma.com

Exchange:

NYSE

Full time employees:

239

Industry:

Biotechnology

Sector:

Healthcare

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

+20 3 4040410

215 Church Street
New Haven, CT 06510

CIK: 0001689813
ISIN: VGG1110E1079
CUSIP: G11196105